{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Best overall response rate by independent radiology review by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in participants with advanced prostate cancer).","groups":[{"description":"Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.","id":"OG000","title":"Rucaparib Cohort A"},{"description":"Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.","id":"OG001","title":"Rucaparib Cohort B"}],"populationDescription":"No data were collected as the independent radiology review was not performed.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until disease progression (up to approximately 2 years)","title":"Overall Response Rate by Independent Radiology Review","type":"SECONDARY"}